Abstract
BackgroundAlzheimer's disease (AD) is associated with deposition of amyloid β (Aβ) in the brain, which is reflected by low concentration of the Aβ1-42 peptide in the cerebrospinal fluid (CSF). There are at least 15 additional Aβ peptides in human CSF and their relative abundance pattern is thought to reflect the production and degradation of Aβ. Here, we test the hypothesis that AD is characterized by a specific CSF Aβ isoform pattern that is distinct when comparing sporadic AD (SAD) and familial AD (FAD) due to different mechanisms underlying brain amyloid pathology in the two disease groups.ResultsWe measured Aβ isoform concentrations in CSF from 18 patients with SAD, 7 carriers of the FAD-associated presenilin 1 (PSEN1) A431E mutation, 17 healthy controls and 6 patients with depression using immunoprecipitation-mass spectrometry. Low CSF levels of Aβ1-42 and high levels of Aβ1-16 distinguished SAD patients and FAD mutation carriers from healthy controls and depressed patients. SAD and FAD were characterized by similar changes in Aβ1-42 and Aβ1-16, but FAD mutation carriers exhibited very low levels of Aβ1-37, Aβ1-38 and Aβ1-39.ConclusionSAD patients and PSEN1 A431E mutation carriers are characterized by aberrant CSF Aβ isoform patterns that hold clinically relevant diagnostic information. PSEN1 A431E mutation carriers exhibit low levels of Aβ1-37, Aβ1-38 and Aβ1-39; fragments that are normally produced by γ-secretase, suggesting that the PSEN1 A431E mutation modulates γ-secretase cleavage site preference in a disease-promoting manner.
Highlights
Alzheimer’s disease (AD) is associated with deposition of amyloid b (Ab) in the brain, which is reflected by low concentration of the Ab1-42 peptide in the cerebrospinal fluid (CSF)
We recently identified a set of 18 N- and C-terminally truncated Ab peptides in CSF using immunoprecipitation-mass spectrometry (IP-MS) [14,15]
The California study groups were comprised of 7 subjects carrying the FADassociated presenilin 1 (PSEN1) A431E mutation, 12 patients with sporadic AD (SAD) and 17 healthy controls (Table 1)
Summary
Alzheimer’s disease (AD) is associated with deposition of amyloid b (Ab) in the brain, which is reflected by low concentration of the Ab1-42 peptide in the cerebrospinal fluid (CSF). Pathological hallmarks of Alzheimer’s disease (AD) include synaptic and neuronal degeneration along with extracellular deposits of amyloid b protein (Ab) in senile plaques in the cerebral cortex [1]. These changes are reflected in vivo by elevated tau protein concentrations and reduced levels of the aggregation prone 42 amino acid isoform of Ab (Ab1-42) in the cerebrospinal fluid (CSF) [2,3]. More than 160 distinct AD-promoting missense mutations have been identified in PSEN1 and three in PSEN2
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.